The IDRA chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the IDRA chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The IDRA stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View IDRA Detailed Price Forecast - CNN Money||View IDRA Detailed Summary - Google Finance|
|View IDRA Detailed Summary - Yahoo! Finance||View IDRA Stock Research & Analysis - Zacks.com|
|View IDRA Trends & Analysis - Trade-Ideas||View IDRA Major Holders - Barrons|
|View IDRA Call Transcripts - NASDAQ||View IDRA Breaking News & Analysis - Seeking Alpha|
|View IDRA Annual Report - CompanySpotlight.com||View IDRA OTC Short Report - OTCShortReport.com|
|View IDRA Fundamentals - TradeKing||View IDRA SEC Filings - Bar Chart|
|View Historical Prices for IDRA - The WSJ||View Performance/Total Return for IDRA - Morningstar|
|View the Analyst Estimates for IDRA - MarketWatch||View the Earnings History for IDRA - CNBC|
|View the IDRA Earnings - StockMarketWatch||View IDRA Buy or Sell Recommendations - MacroAxis|
|View the IDRA Bullish Patterns - American Bulls||View IDRA Short Pain Metrics - ShortPainBot.com|
|View IDRA Stock Mentions - StockTwits||View IDRA Stock Mentions - PennyStockTweets|
|View IDRA Stock Mentions - Twitter||View IDRA Investment Forum News - Investor Hub|
|View IDRA Stock Mentions - Yahoo! Message Board||View IDRA Stock Mentions - Seeking Alpha|
|View Insider Transactions for IDRA - SECform4.com||View Insider Transactions for IDRA - Insider Cow|
|View IDRA Major Holdings Summary - CNBC||View Insider Disclosure for IDRA - OTC Markets|
|View Insider Transactions for IDRA - Yahoo! Finance||View Institutional Holdings for IDRA - NASDAQ|
|View IDRA Stock Insight & Charts - FinViz.com||View IDRA Investment Charts - StockCharts.com|
|View IDRA Stock Overview & Charts - BarChart||View IDRA User Generated Charts - Trading View|
Idera Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference
Posted on Friday January 04, 2019
Idera Pharmaceuticals, Inc. (IDRA) today announced that the company will present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time) at the Westin St. Francis Hotel in San Francisco. An archived version will also be available on the company’s website after the event for 90 days. As a convenience to investors, a copy of the company’s presentation will be posted on the Idera corporate website at 7:30 a.m. Eastern Time on Monday, January 7, 2019.
Today's Research Reports on Trending Tickers: Johnson & Johnson and Idera Pharmaceuticals
Posted on Monday December 17, 2018
NEW YORK, NY / ACCESSWIRE / December 17, 2018 / Both Johnson & Johnson and Idera Pharmaceuticals were big losers in Friday’s trading session. J&J tumbled on a Reuters story that alleged it knew about its baby powder having asbestos for decades while Idera announced data from an ongoing phase 2 trial that were actually encouraging. Johnson & Johnson shares were tanking on Friday, on a Retuers story that the company had known for decades that its baby powder has asbestos.
Idera Pharmaceuticals Presents Clinical Safety and Efficacy Update from the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor Treatment
Posted on Friday December 14, 2018
Idera Pharmaceuticals, Inc. (IDRA) today is presenting data from the ongoing phase 2 expansion of the ILLUMINATE-204 trial investigating tilsotolimod, Idera’s intratumorally-delivered toll-like receptor 9 (TLR9) agonist, in combination with ipilimumab (Yervoy®*).
Idera Pharmaceuticals to Provide ILLUMINATE-204 Clinical Data Update on Friday, December 14, 2018
Posted on Wednesday December 12, 2018
Idera Pharmaceuticals, Inc. (IDRA), a clinical-stage biopharmaceutical company focused on the development and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined patient populations with serious unmet needs, today announced that it plans to release an update on clinical data from the ongoing Phase 2 trial of the combination of intratumoral tilsotolimod and ipilimumab for unresectable or metastatic melanoma following failure of anti-PD-1 inhibitor treatment prior to the opening of the U.S. financial markets on Friday, December 14, 2018. To participate in the conference call, please dial (844) 882-7837 (domestic) and (574) 990-9824 (international). The webcast can be accessed live or in archived form in the “Investors” section of the company’s website at www.iderapharma.com. The company will be posting a slide presentation to the Idera corporate website in the “Investors” section which will be referenced during the conference call.